Effects of risedronate on fracture risk in postmenopausal women with osteopenia
about
Drugs for pre-osteoporosis: prevention or disease mongering?Validated risk rule using computerized data to identify males at high risk for fracture.Once-monthly risedronate for postmenopausal osteoporosisClinical role of bisphosphonate therapy.Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia.Should there be a fracas over FRAX and other fracture prediction tools?: Comment on "A comparison of prediction models for fractures in older women".Changes in Nonosteoporotic Bone Density and Subsequent Fractures in WomenFRAX(®) with and without bone mineral density.FRAX and fracture prediction without bone mineral density.The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis.Comparing fracture absolute risk assessment (FARA) tools: an osteoporosis clinical informatics tool to improve identification and care of men at high risk of first fracture.Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men.Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass.What's in a name? What constitutes the clinical diagnosis of osteoporosis?clinical risk factors for osteoporosis in Ireland and the UK: a comparison of FRAX and QFractureScores.Denosumab - a new medication in the treatment of postmenopausal osteoporosis.Fracture risk before and after total hip replacement in patients with osteoarthritis: Potential benefits of bisphosphonate use
P2860
Q24649128-7399FB16-B7B2-472B-B785-839D99C743D3Q33896095-F6EB877A-76A1-4852-A4FD-483197AD4601Q34272000-246F5AB5-D657-430E-B692-2A2CC77CD963Q36311593-F892AF70-037A-4B9E-861C-0AB2CB44F16CQ36989628-9E303F45-5B4E-40D0-BDC0-0508687E696BQ37094410-151FE078-2263-4877-8895-EF7D3790CD2AQ37163823-22CAA889-EE29-476C-B726-577C2E4583EEQ37953297-0CF36228-4BB7-4663-8AA6-A668E0140E7DQ38613173-B246B76F-A06F-4224-A4C0-FC03A3DB3F39Q38653057-167D1E84-73F0-4387-B59D-0ED36860D580Q41355465-655DC0D1-9FEA-4199-AAF9-F32755CF1839Q44907080-A1D464A9-D47A-4413-80A1-62ADD813DAEBQ45323286-13400638-4914-46D5-B6CA-B40080C79EB2Q46393065-1642B18C-DC95-42BA-BD4D-8D2AC0466554Q50778920-BA9620DF-DD9B-42FA-9F4F-61C0557850F5Q51373499-88D9FB5B-895A-49EF-8F8E-40B663EB7003Q51454005-CFFFF074-5E70-4080-BE3D-B9C0302EEB25Q52673042-0081FD30-D55D-420C-AE05-026DA82DE405Q57417070-4E68D28B-818D-4D4B-B8FA-958DB5B11172
P2860
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@ast
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@en
type
label
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@ast
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@en
prefLabel
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@ast
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@en
P2093
P2860
P1476
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-007-0493-Y
P407
P577
2007-10-30T00:00:00Z